Clinical experience following implementation of routine SPECT-CT imaging following 131-iodine administration for thyroid cancer.
Sara AhmadiAlexandra ColemanNathalie Silva de MoraisIñigo LandaTheodora PappaAlex KangMatthew I KimEllen MarquseeErik K AlexanderPublished in: Endocrine connections (2022)
Synergistic SPECT-CT imaging in addition to planar nuclear scintigraphy adds limited clinical value to thyroid cancer patients harboring a low risk of distant metastases, while frequently identifying clinically insignificant findings. These data from a typical cohort of patients receiving standard thyroid cancer care provide insight into the routine use of SPECT-CT in such patients.
Keyphrases
- dual energy
- image quality
- pet ct
- computed tomography
- contrast enhanced
- high resolution
- end stage renal disease
- positron emission tomography
- newly diagnosed
- clinical practice
- chronic kidney disease
- primary care
- healthcare
- prognostic factors
- lymph node
- electronic health record
- peritoneal dialysis
- quality improvement
- cancer therapy
- patient reported
- data analysis